Veristat Appoints Gabriela Rosu, M.D., to Lead Growing Medical Affairs Team
Veristat Appoints New Chief Commercial Officer
Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector
Massachusetts-based CRO Veristat picked up biometrics trial specialist Instat Clinical Research in a move to boost its services and experience.
Veristat Acquires Biometrics-focused Instat Clinical Research
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded global clinical research organization (CRO), has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory and medical communication documents of the highest quality to the biopharmaceutical industry. The acquisition strengthens Veristat’s ability to meet growing client demand in one of its highest-valued service areas as the range of clinical trial content expands and the importance of regulatory documentation increases.
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded global clinical research organization (CRO) and regulatory consultancy, shared today the addition of three seasoned leaders to Veristat’s Executive team. The appointments reflect Veristat’s rapid rate of global growth, supporting sponsors in overcoming the challenges of operating in complex and highly regulated clinical environments.
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated HIPRA for marketing authorization by the European Medicines Agency (EMA) and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age. BIMERVAX® is the first bivalent recombinant protein vaccine against the virus to be authorized in the European Union and the first human health vaccine to be designed and developed in Spain.
Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
Veristat Presents Integrated, Customized DCT Solutions at the DTRA Annual Meeting